HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MLSS
Milestone Scientific Inc.
There isn't enough reported data to score MLSS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MLSS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MLSS's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MLSS PE Valuation
MLSS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MLSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
MLSS has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MLSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.05 | +$0.04 |
| Q1 2026 | -$0.06 | +$0.01 |
| Q4 2025 | -$0.07 | $0.00 |
| Q3 2025 | -$0.08 | -$0.01 |
| Q2 2025 | -$0.09 | -$0.02 |
| Q1 2025 | -$0.07 | +$0.03 |
| Q4 2024 | -$0.07 | +$0.03 |
| Q3 2024 | -$0.07 | +$0.03 |
MLSS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MLSS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MLSS on profitability, with a higher operating margin.
MLSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.8M | +22% |
| Q1 2026 | $2.2M | -3.2% |
| Q4 2025 | $2.1M | +2.2% |
| Q3 2025 | $2.4M | -6.1% |
| Q2 2025 | $2.3M | +25% |
| Q1 2025 | $2.2M | -0.7% |
| Q4 2024 | $2M | -11% |
| Q3 2024 | $2.5M | +22% |
MLSS's revenue has held roughly level: $3M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -37% | +27 points |
| Q1 2026 | -38% | +51 points |
| Q4 2025 | -52% | +49 points |
| Q3 2025 | -48% | +10 points |
| Q2 2025 | -64% | +32 points |
| Q1 2025 | -89% | -24 points |
| Q4 2024 | -101% | -14 points |
| Q3 2024 | -58% | +15 points |
MLSS's operating margin was −37% last quarter, up 27 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
MLSS has the stronger cash trend. Its trailing FCF is up 46% versus its history, compared with HIMS at down 84%.
MLSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$589.3K | +$1.2M |
| Q1 2026 | $85.2K | +$1.1M |
| Q4 2025 | -$229.2K | +$1.3M |
| Q2 2025 | -$1.8M | -325% |
| Q1 2025 | -$1M | +$210K |
| Q4 2024 | -$1.5M | -$265.7K |
| Q3 2024 | -$973.9K | +$79.3K |
| Q2 2024 | $783.7K | +$1.8M |
MLSS has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MLSS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MLSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +8.1M shares |
| 1 year | +13% | +11.1M shares |
| 3 years | +29% | +20.8M shares |
| 5 years | +35% | +23.9M shares |
| Available history | +95% | +45.4M shares |
MLSS has 93M diluted shares, up 13% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MLSS Net Leverage
MLSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MLSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 4.7 | Oversold |
MLSS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MLSS PE vs Healthcare Sector
MLSS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MLSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.33 | 12% below |
| 20 week MA | $0.39 | 26% below |
| 50 week MA | $0.35 | 17% below |
| 100 week MA | $0.57 | 49% below |
| 200 week MA | $0.70 | 59% below |
MLSS is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MLSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.38 | $2.02 | +46% |
| 2021 | $2.02 | $2.13 | +5.4% |
| 2022 | $2.13 | $0.45 | -79% |
| 2023 | $0.45 | $0.69 | +53% |
| 2024 | $0.69 | $0.88 | +28% |
| 2025 | $0.88 | $0.29 | -67% |
| 2026 YTD | $0.29 | $0.29 | 0% |
MLSS has the edge over HIMS on returns for 2026, with the stronger performance.